Comparison of radiation therapy alone and concurrent chemoradiation therapy in stage III cervical cancer: A multicenter retrospective study
- Author(s)
- JONG-MIN LEE; SEO-YUN TONG; KWANG-BEOM LEE; YOUNG-TAE KIM; YOUNG-JAE KIM; JAE WEON KIM; SEOK-MO KIM; CHI-HEUM CHO; KI-TAE KIM; YOUNG-LAE CHO; KYU-CHAN LEE
- Keimyung Author(s)
- Cho, Chi Heum
- Department
- Dept. of Obstetrics & Gynecology (산부인과학)
- Journal Title
- Acta Obstetricia et Gynecologica Scandinavica
- Issued Date
- 2009
- Volume
- 88
- Issue
- 6
- Abstract
- Objective. To evaluate whether concurrent chemoradiation therapy (CRT) improves overall survival as compared to
radiation therapy (RT) alone in stage III cervical cancers. Design. A multicenter retrospective review. Setting. Nine tertiary
medical centers in Korea. Population. A total of 277 patients treated for stage III cervical cancer without para-aortic lymph
node (PALN) metastasis based on clinical staging workup from 1996 to 2003. Methods. Medical and histopathological
record review. Main outcome measures. Disease-specific overall survival. Results. CRT and RT alone were performed in 172
and 105 patients, respectively. There was no significant difference in disease-specific overall survival between the CRTand
RT alone arms based on clinical staging workup, even though the CRT arm was characterized by younger age, more
favorable performance status and lower pretreatment blood urea nitrogen level as compared to the RT alone arm. In the
CRTarm, three patients succumbed to treatment-related death. Conclusion. CRT does not improve the overall survival rate
in stage III cervical cancer as compared to RTalone based on clinical staging workup for PALN status. Special care needs to
be taken regarding optimal dose and duration of RT, use of brachytherapy, anemia control and accurate pretreatment
staging workup to improve survival outcome in patients with stage III cervical cancer.
Key words: Cancer, cervix, chemotherapy, radiation, survival
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.